Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer.
Seth
Aditya
A
Anderson
Duncan P
DP
Albiani
David A
DA
Barton
Jason J S
JJ
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D007093:Imidazoles / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D008297:Male; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D016727:Orbital Pseudotumor / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D000077211:Zoledronic Acid
D000894:Anti-Inflammatory Agents, Non-Steroidal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D000077211:Zoledronic Acid; D011241:Prednisone; D007052:Ibuprofen